• 1
    Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279290.
  • 2
    McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55: 1520.
  • 3
    Schultz E, Gummert J, Mohr F, Oellerich M. Azathiopurine-induced myelosuppression in thiopurine methyltransferase deficiency heart transplant recipient. Lancet 1993; 341: 436.
  • 4
    Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 94: 64446449.
  • 5
    Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferese pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 6073.
  • 6
    Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58: 694702.
  • 7
    De la Moureyre CS, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879887.
  • 8
    Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371376.DOI: 10.1093/hmg/8.2.371
  • 9
    Collie-Duguid ESR, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, McLeod HL. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 3742.
  • 10
    Ameyaw MM, Collie-Duguid ESR, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367370.DOI: 10.1093/hmg/8.2.367
  • 11
    Otterness DM, Szumlanski CL, Wood TC, Weinshilboum RM. Human thiopurine methyltransferese pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest 1998; 101: 10361044.
  • 12
    De la Moureyre CS, Debuysere H, Sabbagh N, et al. Detection of known and new mutations in the thiopurine S-methyltransferese gene by single-strand conformation polymorphism analysis. Human Mut 1998; 12: 177185.
  • 13
    Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferese deficiency: Genetic Basis for Azathioprine and Mercaptopurine intolerance. Ann Intern Med 1997; 126: 608614.
  • 14
    Hiratuka M, Inoue T, Omori F, Agatuma Y, Mizugaki M. Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res 2000; 14: 9195.
  • 15
    Ishioka S, Hiyama K, Sato H, et al. Thipurine methyltransferase genotype and the toxicity of azathiopurine in Japanese. Intern Med 1999; 38: 944947.
  • 16
    Hiratuka M, Inoue T, Omori F, Agatuma Y, Kishikawa Y, Mizugaki M. Detection assay of rare variants of the thiopurine methyltransferase gene by PCR-RFLP using a mismatch primer in a Japanese population. Biol Pharm Bull 2000; 23: 10901093.